Tuesday, March 25, 2014

The Motley Fool: Is Incyte Corporation Overvalued?

One of the secrets to successful stockpicking in the biotech sector is adequately valuing and pricing the risk/reward profile of a company's pipeline. Almost every biotech looks cheap if an investor just assumes that everything will work as planned, but the reality is that only a small percentage of pipeline prospects live up to their potential. In the case of Incyte (NASDAQ: INCY  ) , this company does have a solid product in Jakafi, but it seems as though the Street is already factoring in a fair bit of success for the company's early stage pipeline.

Follow this link to the full article:
Is Incyte Corporation Overvalued?

No comments: